Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs

Cell Biology International

Volumn 38, Issue 4, 2014, Pages 452-461

  Dou, Jun ^a   He, Xiangfeng ^a,b   Liu, Yurong ^a   Wang, Yaqian ^a   Zhao, Fengshu ^a   Wang, Xiaoying ^a   Chen, Dengyu ^a   Shi, Fangfang ^a   Wang, Jing ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Cancer stem cells; Epithelial mesenchymal transition; Melanoma; RNA interference; Zinc finger e box binding protein 1

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR ZEB1; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENICITY; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; MELANOMA CELL; METASTASIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RNA SEQUENCE; TUMOR GENE; TUMOR INVASION; ZEB1 GENE;

CANCER STEM CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; MELANOMA; RNA INTERFERENCE; ZINC FINGER E-BOX-BINDING PROTEIN 1;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; HOMEODOMAIN PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIMENTIN;

EID: 84895884486     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1002/cbin.10223     Document Type: Article

References (33)

1. Bastiaannet E, Beukema JC, Hoekstra HJ (2005) Radiation therapy following lymph node dissection inmelanoma patients: treatment, outcome and complications. Cancer Treat Rev 31: 18-26.
2. Bendoraite A, Knouf EC, Garg KS (2010) Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 116: 117-25.
3. Burk U, Schubert J, Wellner U, SchmalhoferO, Vincan E, Spaderna S, Brabletz T (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMTand invasion in cancer cells. EMBO Rep 9: 582-89.
4. +ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res 6: 50.
5. Chen D, Wang J, Zhang Y, Chen J, Yang C, CaoW, Zhang H, Liu Y, Dou J (2013) Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells. Int J Gynecol Cancer 23: 1357-66.
6. + ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol 14: 7.
7. Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L, Zhao F, Jiang C, HuW, Hu K, Gu N (2007) Isolation and identification of cancer stem like cells from murine melanoma cell lines. Cell Mol Immunol 4: 528-33.
8. Dou J, Wen P, HuW, Li Y, Wu Y, Liu C, Zhao F, Hu K, Wang J, Jiang C, He X, Gu N (2009) Identifying tumor stem-like cells in mouse melanoma cell lines by analyzing the characteristics of side population cells. Cell Biol Int. 33: 807-15.
9. Elson-Schwab I, Lorentzen A, Marshall CJ (2010) MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS ONE 5: pii.e13176.
10. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445: 851-57.
11. He X, Wang J, Zhao F, Yu F, Chen D, Cai K, Yang C, Chen J, Dou J (2012) Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse. Immunol Res 52: 240-49.
12. HuW, Wang J, Dou J, He X, Zhao F, Jiang C, Yu F, Hu K, Chu L, Li X, Gu N (2011) Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplant 20: 669-80.
13. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC (2010) Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 8: 27.
14. Liu S, Tetzlaff MT, Liu A, Liegl-Atzwanger B, Guo J, Xu X (2012) Loss of microRNA-205 expression is associated with melanoma progression. Lab Invest 92: 1084-96.
15. Mani SA, GuoW, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-15.
16. MatsuiW, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ (2004) Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-36.
17. Murielle M, Surinder KB (2012) Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol 3: 32-42.
18. Ngora H, Galli UM, Miyazaki K, Zöller M (2012) Membranebound and exosomal metastasis-associated C4.4A promotes migration by associating with the α(6)β(4) integrin and MT1-MMP. Neoplasia 14: 95-107.
19. Qu X, Shen L, Zheng Y, Cui Y, Feng Z, Liu F, Liu J (2014) A signal transduction pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with progression in human melanoma. J Invest Dermatol 134: 159-67.
20. Quintana E, ShackletonM, FosterHR, FullenDR, SabelMS, Johnson TM, Morrison SJ (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-23.
21. Ouyang L, Shen LY, Li T, Liu J (2006) Inhibition effect of oncostatin M on metastatic human lung cancer cells 95D in vitro and on murinemelanoma cells B16BL6 in vivo. Biomed Res 27: 197-202.
22. Romano S, Staibano S, Greco A, Brunetti A, Nappo G, Ilardi G, Martinelli R, Sorrentino A, Di Pace A, Mascolo M, Bisogni R, Scalvenzi M, Alfano B, Romano MF (2013) FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death Dis 4: e578.
23. Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J (2012) PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer 106: 1486-94.
24. Schatton T, Frank MH (2009) Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 1176: 154-69.
25. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH (2008) Identification of cells initiating human melanomas. Nature 451: 345-49.
26. Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, Kusewitt DF (2012) Slug expression during melanoma progression. Am J Pathol 180: 2479-89.
27. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelialmesenchymal transitions in development and disease. Cell 139: 871-90.
28. Vaibhav S, Robert HS (2010) Potential for therapeutic targeting of tumor stem cells. Cancer Sci 101: 16-21.
29. Verhaegen M, Checinska A, Riblett MB, Wang S, Soengas MS (2012) E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene 31: 828-41.
30. Wang J, Cao MG, You CZ, Wang CL, Liu SL, Kai C, Dou J (2012) A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. Cell Mol Biol 58 (Suppl): OL1641-45.
31. Wang J, Zhou D, He X, Wang Y, Hu W, Jiang L, Dou J (2011) Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drugs and tumorigenicity of ovarian cancer cells. Cell Mol Biol 57: OL1606-13.
32. Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE (2012) TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res 72: 6382-92.
33. Zhang H, Wang J, Cai K, Jiang L, Zhou D, Yang C, Chen J, Chen D, Dou J (2012) Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. J Cancer Res Ther 8: 226-31.